SML2288

Sigma-Aldrich

Anidulafungin

≥97% (HPLC)

Sinónimos:
LY 303366, 1-[(4R,5R)-4,5-Dihydroxy-N2-[[4′′-(pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B
Empirical Formula (Hill Notation):
C58H73N7O17
Número de CAS:
Peso molecular:
1140.24
MDL number:
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

SMILES string

CCCCCOC1=CC=C(C2=CC=C(C3=CC=C(C(N[C@H]4C[C@@H](O)[C@@H](O)NC([C@@H]5[C@@H](O)[C@@H](C)CN5C([C@H]([C@H](O)C)NC([C@H]([C@H](O)[C@@H](O)C6=CC=C(O)C=C6)NC([C@@H]7C[C@@H](O)CN7C([C@H]([C@H](O)C)NC4=O)=O)=O)=O)=O)=O)=O)C=C3)C=C2)C=C1

InChI

1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1

InChI key

JHVAMHSQVVQIOT-MFAJLEFUSA-N

Biochem/physiol Actions

Anidulafungin is a semisynthetic echinocandin antifungal. Anidulafungin works by inhibiting the enzyme β(1,3)-D-Glucan synthase and thereby disturbing the integrity of the fungal cell wall. This enzyme does not exist in mammalian systems.

pictograms

Health hazard

signalword

Warning

hcodes

Target Organs

Liver

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Ali Ahmadi et al.
Journal of global antimicrobial resistance, 21, 331-334 (2019-11-13)
Candida parapsilosis (C. parapsilosis) is a common non-albicans Candida species ranked as the second common cause of bloodstream infections. Azole resistance and elevated echinocandin MICs have been reported for these fungi. This study was conducted to determine the interactions between...
Po-Yi Chen et al.
International journal of antimicrobial agents, 55(1), 105820-105820 (2019-10-18)
Evidence supporting the use of an echinocandin alone as an alternative agent for the treatment of Pneumocystis jirovecii pneumonia (PCP) is limited and controversial. This retrospective cohort study was conducted at National Taiwan University Hospital from 1 July 2015 to...
Orawan Tulyaprawat et al.
Frontiers in microbiology, 11, 934-934 (2020-06-09)
Candidemia, a bloodstream infection caused by genus Candida, has a high mortality rate. Candida albicans was previously reported to be the most common causative species among candidemia patients. However, during the past 10 years in Thailand, Candida tropicalis has been...
Harsimran Kaur et al.
Indian journal of medical microbiology, 38(1), 110-116 (2020-07-29)
Candidaemia is a major cause of morbidity and mortality of hospitalised patients, especially in developing countries. This study was conducted to monitor any change in species distribution and antifungal susceptibility pattern of Candida species causing candidaemia over the last 20...
Lalitha Gade et al.
Frontiers in genetics, 11, 554-554 (2020-06-27)
The recent emergence of a multidrug-resistant yeast, Candida auris, has drawn attention to the closely related species from the Candida haemulonii complex that include C. haemulonii, Candida duobushaemulonii, Candida pseudohaemulonii, and the recently identified Candida vulturna. Here, we used antifungal...

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.